This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
OCPNY or EW: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
OCPNY vs. EW: Which Stock Is the Better Value Option?
What Makes Olympus Corp. (OCPNY) a Good Fit for "Trend Investing"
by Zacks Equity Research
Olympus Corp. (OCPNY) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.
OCPNY vs. IDXX: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
OCPNY vs. IDXX: Which Stock Is the Better Value Option?
Here's Why Momentum in Olympus Corp. (OCPNY) Should Keep going
by Zacks Equity Research
Olympus Corp. (OCPNY) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through our "Recent Price Strength" screen.
OCPNY or IDXX: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
OCPNY vs. IDXX: Which Stock Is the Better Value Option?
Here's Why Olympus Corp. (OCPNY) is a Great Momentum Stock to Buy
by Zacks Equity Research
Does Olympus Corp. (OCPNY) have what it takes to be a top stock pick for momentum investors? Let's find out.
Financial Market Cycles: Zacks July Market Strategy
by John Blank
We have reached a critical inflection point: where thinking about financial market cycles is a gripping trader and investor topic. Let's do a deeper dive into key relationships.
The Zacks Analyst Blog Highlights The Kroger, Olympus and Komatsu
by Zacks Equity Research
The Kroger, Olympus and Komatsu are part of Zacks top Analyst Blog.
Time to Buy Chinese Large Caps? Global Week Ahead
by John Blank
With officials pledging support for markets and the economy, and easing their tech sector crackdowns, investment banks are again rushing to slap Buy labels on Chinese shares.
OCPNY vs. EW: Which Stock Is the Better Value Option?
by Zacks Equity Research
OCPNY vs. EW: Which Stock Is the Better Value Option?
OCPNY vs. EW: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
OCPNY vs. EW: Which Stock Is the Better Value Option?
Here's What Could Help Olympus Corp. (OCPNY) Maintain Its Recent Price Strength
by Zacks Equity Research
Olympus Corp. (OCPNY) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through our "Recent Price Strength" screen.
Olympus Corp. (OCPNY) Upgraded to Buy: Here's Why
by Zacks Equity Research
Olympus Corp. (OCPNY) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Recent Price Trend in Olympus Corp. (OCPNY) is Your Friend, Here's Why
by Zacks Equity Research
If you are looking for stocks that are well positioned to maintain their recent uptrend, Olympus Corp. (OCPNY) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.
OCPNY or EW: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
OCPNY vs. EW: Which Stock Is the Better Value Option?
Here's Why "Trend" Investors Would Love Betting on Olympus Corp. (OCPNY)
by Zacks Equity Research
Olympus Corp. (OCPNY) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.
Zacks.com featured highlights include: Nitto, Kulicke & Soffa, Olympus and Industrias Bachoco
by Zacks Equity Research
Zacks.com featured highlights include: Nitto, Kulicke & Soffa, Olympus and Industrias Bachoco
Forget Profit, Bet on 4 Stocks With Increasing Cash Flows
by Zacks Equity Research
Cash is the key for a company's existence, development and success.
The Zacks Analyst Blog Highlights: Cerner, AmerisourceBergen, Fresenius and Olympus
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Cerner, AmerisourceBergen, Fresenius and Olympus
3 Favorable Trends Dispelling Tax-Repeal Worries in MedTech
by Nabaparna Bhattacharya
Here we analyze how the U.S. MedTech space is gearing up to counter the disquieting CBO projections regarding federal deficit.
Medical Product Stocks' Earnings Due on May 1: CAH & OCPNY
by Zacks Equity Research
Here we take a look at two major Medical Product bigwigs, which are expected to release their earnings results on May 1.